Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.
Identifieur interne : 000813 ( Main/Curation ); précédent : 000812; suivant : 000814Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.
Auteurs : Gary R. Lichtenstein [États-Unis]Source :
- Gastroenterology & hepatology [ 1554-7914 ] ; 2017.
PubMed: 29230138
PubMed Central: PMC5718178
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000813
Links to Exploration step
pubmed:29230138Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.</title><author><name sortKey="Lichtenstein, Gary R" sort="Lichtenstein, Gary R" uniqKey="Lichtenstein G" first="Gary R" last="Lichtenstein">Gary R. Lichtenstein</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29230138</idno><idno type="pmid">29230138</idno><idno type="pmc">PMC5718178</idno><idno type="wicri:Area/Main/Corpus">000813</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000813</idno><idno type="wicri:Area/Main/Curation">000813</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.</title><author><name sortKey="Lichtenstein, Gary R" sort="Lichtenstein, Gary R" uniqKey="Lichtenstein G" first="Gary R" last="Lichtenstein">Gary R. Lichtenstein</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia</wicri:cityArea></affiliation></author></analytic><series><title level="j">Gastroenterology & hepatology</title><idno type="ISSN">1554-7914</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29230138</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1554-7914</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Gastroenterology & hepatology</Title><ISOAbbreviation>Gastroenterol Hepatol (N Y)</ISOAbbreviation></Journal><ArticleTitle>Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.</ArticleTitle><Pagination><MedlinePgn>612-614</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>Gary R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Professor of Medicine Director, Center for Inflammatory Bowel Disease Perelman School of Medicine of the University of Pennsylvania Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterol Hepatol (N Y)</MedlineTA><NlmUniqueID>101262648</NlmUniqueID><ISSNLinking>1554-7914</ISSNLinking></MedlineJournalInfo><CoiStatement>Dr Lichtenstein has consulted for Abbott Corporation/AbbVie, Actavis, Alaven, Celgene, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, Takeda, and UCB; conducted research for Celgene, Janssen Orthobiotech, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, and UCB; received honorarium (CME Program) from Ironwood, Luitpold/American Regent, Merck, and Romark; and received funding to the University of Pennsylvania (IBD Fellow Education) from Janssen Orthobiotech, Pfizer Pharmaceuticals, and Takeda.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29230138</ArticleId><ArticleId IdType="pmc">PMC5718178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2013 Oct;72(10):1613-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23687260</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Gastroenterol Hepatol. 2017 Jan;14 (1):22-31</Citation><ArticleIdList><ArticleId IdType="pubmed">27729659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2017 Jan;11(1):26-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27927718</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2017 Apr;45(8):1043-1057</Citation><ArticleIdList><ArticleId IdType="pubmed">28239873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2013 Oct;72(10):1605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23687259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:29230138
|texte= Introduction to Biosimilar Use in Patients With Inflammatory Bowel Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:29230138" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |